Cargando…
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study
Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients ho...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617857/ https://www.ncbi.nlm.nih.gov/pubmed/34834543 http://dx.doi.org/10.3390/jpm11111192 |
_version_ | 1784604607499993088 |
---|---|
author | Ashcraft, Kristine Moretz, Chad Schenning, Chantelle Rojahn, Susan Vines Tanudtanud, Kae Magoncia, Gwyn Omar Reyes, Justine Marquez, Bernardo Guo, Yinglong Erdemir, Elif Tokar Hall, Taryn O. |
author_facet | Ashcraft, Kristine Moretz, Chad Schenning, Chantelle Rojahn, Susan Vines Tanudtanud, Kae Magoncia, Gwyn Omar Reyes, Justine Marquez, Bernardo Guo, Yinglong Erdemir, Elif Tokar Hall, Taryn O. |
author_sort | Ashcraft, Kristine |
collection | PubMed |
description | Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients hospitalized with COVID-19, we retrospectively reviewed medical and pharmacy claims from 6025 Medicare Advantage members hospitalized with COVID-19. Patients with a moderate or high pharmacogenetic interaction probability (PIP), which indicates the likelihood that testing would identify one or more clinically actionable gene–drug or gene–drug–drug interactions, were hospitalized for 9% (CI: 4–15%; p < 0.001) and 16% longer (CI: 8–24%; p < 0.001), respectively, compared to those with low PIP. Risk adjustment factor (RAF) score, a commonly used measure of disease burden, was not associated with LOS. High PIP was significantly associated with 12–22% longer LOS compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or chronic obstructive pulmonary disease (COPD). A greater drug–drug interaction risk was associated with 10% longer LOS among patients with two or three chronic conditions. Thus, unmanaged pharmacogenomic risk was associated with longer LOS in these patients and managing this risk has the potential to reduce LOS in severely ill patients, especially those with chronic conditions. |
format | Online Article Text |
id | pubmed-8617857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86178572021-11-27 Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study Ashcraft, Kristine Moretz, Chad Schenning, Chantelle Rojahn, Susan Vines Tanudtanud, Kae Magoncia, Gwyn Omar Reyes, Justine Marquez, Bernardo Guo, Yinglong Erdemir, Elif Tokar Hall, Taryn O. J Pers Med Article Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients hospitalized with COVID-19, we retrospectively reviewed medical and pharmacy claims from 6025 Medicare Advantage members hospitalized with COVID-19. Patients with a moderate or high pharmacogenetic interaction probability (PIP), which indicates the likelihood that testing would identify one or more clinically actionable gene–drug or gene–drug–drug interactions, were hospitalized for 9% (CI: 4–15%; p < 0.001) and 16% longer (CI: 8–24%; p < 0.001), respectively, compared to those with low PIP. Risk adjustment factor (RAF) score, a commonly used measure of disease burden, was not associated with LOS. High PIP was significantly associated with 12–22% longer LOS compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or chronic obstructive pulmonary disease (COPD). A greater drug–drug interaction risk was associated with 10% longer LOS among patients with two or three chronic conditions. Thus, unmanaged pharmacogenomic risk was associated with longer LOS in these patients and managing this risk has the potential to reduce LOS in severely ill patients, especially those with chronic conditions. MDPI 2021-11-12 /pmc/articles/PMC8617857/ /pubmed/34834543 http://dx.doi.org/10.3390/jpm11111192 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ashcraft, Kristine Moretz, Chad Schenning, Chantelle Rojahn, Susan Vines Tanudtanud, Kae Magoncia, Gwyn Omar Reyes, Justine Marquez, Bernardo Guo, Yinglong Erdemir, Elif Tokar Hall, Taryn O. Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
title | Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
title_full | Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
title_fullStr | Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
title_full_unstemmed | Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
title_short | Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
title_sort | unmanaged pharmacogenomic and drug interaction risk associations with hospital length of stay among medicare advantage members with covid-19: a retrospective cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617857/ https://www.ncbi.nlm.nih.gov/pubmed/34834543 http://dx.doi.org/10.3390/jpm11111192 |
work_keys_str_mv | AT ashcraftkristine unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT moretzchad unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT schenningchantelle unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT rojahnsusan unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT vinestanudtanudkae unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT magonciagwynomar unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT reyesjustine unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT marquezbernardo unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT guoyinglong unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT erdemireliftokar unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT halltaryno unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy |